Ongoing Clinical Research

OIC is at the forefront of clinical trials and cutting edge technology. Here, you can research study opportunities for HIV vaccines, HIV medications, and Hepatitis C medications.

If you are eligible, you will receive study drugs, labs, and medical treatments related to the study at no cost.

HIV STUDIES

  • GSK200911 (CURRENTLY ENROLLING)
    • A phase 2a, Multicenter, randomized, adaptive, open-label, dose ranging study to evaluate the antiviral effect, safety, tolerability and pharmacokinetics of Cobicstat-boosted GSK2838232 monotherapy over 10 days in HIV-1 infected treatment-Naïve adults.
  • TMC114-FD2HTX-3002 (CURRENTLY ENROLLING)
    •  Link Pending – A phase 3, randomized, active controlled, double-blind study to evaluate the efficacy and safety of Darunivir /Cobistat/Emtricitabine/TAF once daily fixed dose regimen versus a regimen consisting of darunivir/cobicstat fixed dose combination  co adminstered with Emtricitabine tenofovir fixed doses combination in antiretroviral treatment  niave HIV type 1 infected subjects.
  • ABI-1968-201 (CURRENTLY ENROLLING)
    • Link Pending – Open-Label study to evaulate the safety tolderability and pharmacokinetics of single and multiple doses of topical ABI-1968 in subjects with anal high-grade squamous intraepithelial lesions
  • REPRIEVE (CURRENTLY ENROLLING)
    • People infected with HIV are at risk for cardiovascular disease.  This study will evaluate the use of pitavastatin to reduce the risk of CVD in adults infected with HIV who are on antiretroviral therapy.
  • PRO140_CD03 (CURRENTLY ENROLLING)
    • A phase 2b/3 multicenter study to assess the treatment strategy of using PRO140 SC as long acting single agent maintenance therapy for 48 weeks in virologically suppressed subjects with CCR5 topic HIV-1 Infection.
  • GS-US-382-3961 (CURRENTLY ENROLLING)
    • A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers
  • 204862 (CURRENTLY ENROLLING) 
    • Link Pending – A phase III, ramdomized, multicenter, parallel-group, non-inferioriy study evaluating the efficacy, safety and tolerability of switching to dolutegravir plus lamividine in HIV-1 infected adults who are virologically suppressed
  • GS-US-380-4030 (CURRENTLY ENROLLING)
    • A phase 3, randomized, double-blind study to evaluate the safety and efficacy of switching from a regimen of Dolutegravir and either Emtricitabine/ Tenofovir Alafenamide or Emtricitabine/ Tenoforvir Disoproxil Fumerate to a fixed dose combination of Bictegravir/Emtricitabine/ Tenofovir Alafenamide in Hiv 1 infected subjects who are virologially suppressed.
  • ABI-1968-201 (CURRENTLY ENROLLING)
    • Link Pending – Open-Label study to evaulate the safety tolderability and pharmacokinetics of single and multiple doses of topical ABI-1968 in subjects with anal high-grade squamous intraepithelial lesions
  • PRO140-CD02 (CURRENTLY ENROLLING)
    • A multicenter, randomized, double-blind, placebo controlled trial, followed by a single-arm treatment of PRO140 in combination with optimized background therapy in treatment-experienced HIV-1 subjects.
  • ABI-1968-201 (CURRENTLY ENROLLING)
    • Link Pending – Open-Label study to evaulate the safety tolderability and pharmacokinetics of single and multiple doses of topical ABI-1968 in subjects with anal high-grade squamous intraepithelial lesions

HCV STUDIES

  • 3152-301-002 (CURRENTLY ENROLLING)
    •  A phase 3, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of Cenicriviroc for the treatment of Liver Fibrosis in adult subjects with Nonalcoholic Steatohepatitis.
  • PB-WOTFORHEPC (CURRENTLY ENROLLING)
    • Evaluation of wirelessy observed therapy to optimize adherence in patients with Hepatitis C and increased risk for nonadhearence to treatment.
  • GS-US- 367-2036 (PENDING)
    • A phase 3, open label study to investigate the efficacy and safety of
      Sofosbuvir/Velpatasvir/Voxilaprevir fixed dose combination for 12 weeks with chronic Hepatitis C virus and HIV coinfection who have been previously treated with direct-acting antiviral HCV therapy.
  • 3152-301-002 (CURRENTLY ENROLLING)
    • A phase 3, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of Cenicriviroc for the treatment of Liver Fibrosis in adult subjects with Nonalcoholic Steatohepatitis.
  • GS-US-367-4181 (CURRENTLY ENROLLING)
    • An open-label study to evaulate the safety and efficacy of Sofosbuvir/Velpatasvir/ Voxilaprevir fixed dose combination for 12 weeks in subjects who participated in prior Gilead sponsored HCV treatment.
  • PB-WOTFORHEPC (CURRENTLY ENROLLING)
    • Evaluation of wirelessy observed therapy to optimize adherence in patients with Hepatitis C and increased risk for nonadhearence to treatment.
  • B16-439 (CURRENTLY ENROLLING)
    • A phase 3b, Multicenter, Randomized, Open-Label, Pragmatic study of Glecaprevir / Pibrentasvir (G/P) +/- Ribavirin for GT1 subjects with Chronic Hepatitis C previously treated with Ns5A Inhibitor + Sofosbuvir Therapy.

OTHER STUDIES

  • REPRIEVE (CURRENTLY ENROLLING)
    • People infected with HIV are at risk for cardiovascular disease.  This study will evaluate the use of pitavastatin to reduce the risk of CVD in adults infected with HIV who are on antiretroviral therapy.

 

  • ABI-1968-201
    • Link Pending – Open-Label study to evaulate the safety tolderability and pharmacokinetics of single and multiple doses of topical ABI-1968 in subjects with anal high-grade squamous intraepithelial lesions
  • HIV DUO RD002843 (CURRENTLY ENROLLING)
    • Link Pending – Performance evaluation Elecsys HIV Duo on the cobas e 801 Immunoassay Analyser sample collection

 

Source: ClinicalTrials.gov

Clinical Trial Inquiry

To schedule an appointment with one of our board certified specialists call
(407) 647-3960 or click here to request an appointment.